Bhattacharjee Nabendu, Ganguly Rajendra Prasad, Saha Shyama Prasad
Department of Obstetrics and Gynaecology, R.G. Kar Medical College, Kolkata, India.
Aust N Z J Obstet Gynaecol. 2007 Feb;47(1):23-5. doi: 10.1111/j.1479-828X.2006.00673.x.
To evaluate the efficacy and safety of PGE1 analogue, misoprostol, for inducing abortion or labour during mid-trimester in women who have had a prior Caesarean section (one or more).
Women who had to undergo termination of pregnancy between 13 and 26 weeks of gestation for various indications and who had at least one previous Caesarean section were studied over a period of two and a half years. The standard regimen for misoprostol in all the cases was 400 microg up to 20 weeks of gestation and 200 microg for pregnancies longer than 20 weeks, either vaginally or sublingually every six hours (up to maximum 24 h). A contemporaneous cohort of women undergoing the same procedure for similar indications but without scarred uteri served as control.
Eighty women in the study group underwent termination procedures for unwanted pregnancy, missed abortion, fetal anomaly or fetal death. The median induction-abortion interval was 16.4 h (10-21 h) and did not differ much from that in women without previous Caesarean delivery (median: 15.6 h; range 9.6-20 h), P > 0.05. Misoprostol was found to be safe in our cohort of post-Caesarean women and there was no case of scar rupture or dehiscence. No significant differences in rates of incomplete abortions, blood loss or sepsis were detected in the study group compared to the control group.
The use of misoprostol for mid-trimester pregnancy termination is not contraindicated in women with Caesarean scar and is effective and comparable with those in women without scarred uteri.
评估前列腺素E1类似物米索前列醇用于有过一次或多次剖宫产史的女性在孕中期引产或催产的疗效及安全性。
对因各种指征在妊娠13至26周期间必须终止妊娠且至少有过一次剖宫产史的女性进行了为期两年半的研究。所有病例中米索前列醇的标准方案为:妊娠20周及以内剂量为400微克,妊娠超过20周剂量为200微克,经阴道或舌下给药,每6小时一次(最长24小时)。选取同期因类似指征接受相同手术但子宫无瘢痕的女性作为对照组。
研究组80名女性因意外妊娠、稽留流产、胎儿畸形或胎儿死亡接受了终止妊娠手术。引产至流产的中位间隔时间为16.4小时(10 - 21小时),与无剖宫产史的女性相比差异不大(中位时间:15.6小时;范围9.6 - 20小时),P>0.05。在我们的剖宫产术后女性队列中发现米索前列醇是安全的,没有瘢痕破裂或裂开的病例。与对照组相比,研究组在不完全流产率、失血量或败血症发生率方面未检测到显著差异。
有剖宫产瘢痕的女性在孕中期使用米索前列醇终止妊娠并非禁忌,其效果与子宫无瘢痕的女性相当且有效。